I-MAB (IMAB) has released an update.
I-Mab, a global biotech company, has reported promising results for their innovative cancer drug givastomig at the ESMO 2024 Congress. The drug, intended for advanced gastric cancer treatment, demonstrated efficacy and safety in Phase 1 trials, with positive responses even in heavily pre-treated patients. A Phase 1b study is also in progress to examine givastomig’s potential as a front-line therapy in combination with standard-of-care treatments.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
